



October 17, 2025, Monthly Update

Zhittya's Momentum and Excitement Are Growing!

Preface

Since our September 17, 2025, Monthly Update, we have experienced a tremendous responses and great momentum and excitement.

The response to FGF-1's potential as a rejuvenator of cellular functions has been well-received by many people. In particular, the possibility that Zhittya's FGF-1 could reverse type 2 diabetes has resonated with thousands of people worldwide. We have hundreds of inquiries from individuals all over the world, eager to learn about reversing type 2 diabetes. Never in my life have I seen such an overwhelming response; it seems there is massive "**pent-up demand**" for a treatment to reverse type 2 diabetes.

Over the past 20 years, we have presented in Dubai, Abu Dhabi, Qatar, Kuwait, Bahrain, and throughout Saudi Arabia on topics like heart disease, stroke recovery, and Parkinson's disease. I estimate over 2,000 medical doctors from the Arab Gulf have attended our presentations and joined our Monthly Update email list. Type 2 diabetes is rampant in the Arab Gulf, with some of the highest rates of diabetes in the world. We have had a great response and interest from them. A highly respected medical doctor in Dubai is giving a presentation at the Regenerative Medicine Conference in Dubai on October 24, before an anticipated 500 attendees on Zhittya's treatment for reversing Parkinson's disease—he may

also mention our medicine's potential to reverse type 2 diabetes. See the Events Section.

I have received emails and calls from people across the Indian subcontinent who want our treatment now, regardless of cost. Reports indicate over 220 million people in the Indian subcontinent have diabetes. Many of these people are skinny and do not have an extra ounce of fat, yet they have diabetes.

As a businessman, I have to deal with reality. Our FGF-1 has treated heart disease (the top cause of death in the world), enhanced recovery from strokes, reversed the progression of Parkinson's disease, and more; however, I have never seen as powerful a response to anything as we have witnessed with the reversal of type 2 diabetes. We know that the need is there. We have had thousands of sign-ups for our Medical Research Study to reverse type 2 diabetes in Las Vegas, NV. We are getting calls and emails from people pleading to be treated. Every day, people are learning about and sharing their diabetes nightmare with us and referring their friends to us. To say we have received thousands of emails would be an understatement.

For example, on September 16–17, we attended the National Investment Bankers Association (NIBA) Annual Meeting in Ft. Lauderdale, Florida. NIBA is where mid-sized and small investment banking firms and stockbrokers attend to network and find business, with ~300 in attendance. Because Zhittya has already seen a great response to our Medical Research Funding program for type 2 diabetes, I was eager to explore the possibility of creating more funds in 2026 for other diseases such as peripheral artery disease, dementia, autism, cancer, and heart disease. Could I interest these investment banking firms in helping us find tens of millions of dollars for those future Medical Research Studies from their investors?

I was an investment banker from 1968 to 1998, handling many IPOs. I had been a member of NIBA for around 20 years. At the meeting, I reconnected with some friends from 30 to 40 years ago (back when I was good and skinny). I gave my 15-minute presentation on the diseases our medicine might treat, with the last 3 minutes on what we are doing with type 2 diabetes. After my presentation, we were swamped with people wanting our diabetes treatment. Returning to a group of investment bankers after 25 years is like an Old Wolf returning to the hunting pack. Most surprisingly, these typically money-focused investment bankers (I know, I was one) didn't want to talk about money but about their health. The Centers for Disease Control (CDC) reports 29.2% of people over 65 have diabetes. I expected the older ones to care, but young stockbrokers wanted the medicine

for their mother, aunt, sister, or wife. One guy whom I have known for over 30 years, who owns a stock brokerage firm, told me he has diabetes and thinks half of his customers have diabetes. With the stock market breaking new highs, with IPOs being hot again, with biotech **being hot again**, with trillions of dollars in idle cash looking for a place to invest, I thought that these investment banker wolves would be hungry to make money with what we are doing. Instead, they were concerned about their health, they wanted something to treat type 2 diabetes, and they wanted Zhittya to succeed. **Our timing may be perfect!**

From December 9–11, Vika and I will be presenting at the 12th Annual Family Offices Super Summit in Ft. Lauderdale, FL. Family offices are wealthy families that have set aside parts of their fortune to be managed by themselves and other family members. We attended about 6 years ago and had a good response, but then we did not have a treatment that might reverse type 2 diabetes or a treatment for Parkinson's disease. This time, we believe there will be 200 to 300 wealthy families that are seeking investments and, we believe, treatments for their health. If some of you want to attend, we encourage you to register here: <https://familyoffices.com/super/>.

Maybe some of them will be interested in investing in a new Zhittya Medical Research Fund in 2026 to discover if we can reverse dementia, reverse Alzheimer's, enhance recovery for autism, reconfirm that we can treat small vessel heart disease, and more. It would be great for Zhittya to have 5 to 10 medical research studies ongoing next year to verify we can improve human health with FGF-1. The Michael J. Fox Foundation raised \$370 million last year and over the last 20 years has raised over \$3 billion, yet they cannot point to one Parkinson's patient they have reversed. Zhittya has dosed over 220 sufferers of Parkinson's disease, and we have amazing stories of recovery and improvement. Read Vika's section of this Update on the "Type 2 Diabetes First Glance" of the results and the Parkinson's disease improvements in our patients. Zhittya is a small biotech company that has the drive and hunger to succeed. An old saying is "Hungry dogs hunt better!" Zhittya is your hungry dog in the fight to reverse these diseases!

Last comment, to those of you who question us because "If this were real, Big Pharma would be doing it." For 12 years, numerous medical scientific papers have been published showing that FGF-1 can reverse type 2 diabetes. While Zhittya was dosing Parkinson's disease patients in the British Virgin Islands, we saw that all the type 2 diabetics that we dosed with FGF-1 reversed their diabetes status.

We tried for a year to pay a medical university to conduct a medical research study to re-verify this evidence in the United States. They said yes at the first meeting but then never returned our calls. We finally found a clinic in Las Vegas, obtained Institutional Review Board (IRB) clearance, and we are dosing type 2 diabetics now! Read [Vika's Report](#), especially if you or someone you love has diabetes. We are looking for more good people as volunteers. You can visit cure-diabetes.net to sign up yourself or your loved ones today.

As for Big Pharma and their \$45 billion in annual sales of diabetes drugs (in the USA alone), which do not cure the patients, only treat the symptoms. I guess their annual billion-dollar research department budget did not have any money to read about a possible cure for diabetes in hundreds of publications over the last 12 years. Zhittyia may be small, but we know how to read. It is not the size of the dog in the fight that decides a winner; it is the amount of fight in the dog.

For those of you with diabetes, heart disease, strokes, Parkinson's disease, and other diseases, Zhittyia is your dog in this fight. Not because of our pedigree or our beauty, but **because we must win! It is our nature!** Like a dog guarding sheep, we cannot abandon those of you who need us, no matter the impossibility of the task. A single sheepdog standing up against a pack of wolves or standing against a bear to protect his sheep; we all know he cannot abandon his responsibilities to those he is trusted to protect. It is Zhittyia's nature, and we will not lose. We have been entrusted with this mission, and we will not fail.

Chronic Wounds

Zhittyia's efforts to heal non-healing wounds date back to 1980, when Merck was the patent holder for FGF-1. Merck had a task force to advance FGF-1 to heal wounds. Merck had outstanding results; however, Merck shut down all biotech efforts in 1997 because the new president did not believe in biotech. We bought all of Merck's data and added our own work over the last 20 years. It is reported that 6.5 million Americans have non-healing wounds every year. Most of those are diabetic foot ulcers (DFUs), which will not heal due to the lack of blood flow at the wound site. In 30 years of studies, FGF-1 has closed 100% of open DFUs. It is reported that 5.6 million Americans live with the possibility of the loss of a limb, and annual amputations are around 500,000 per year. I believe Zhittyia's medicine could close most of these wounds and defer or eliminate many amputations. That is important. Our Medical Research Fund to heal chronic wounds is filling up, and I hope we will treat the first patients soon. Here is a link to our landing page for volunteers and investors: cure-wounds.com.

If the investors in the Medical Research Fund to heal chronic wounds make a profit by helping find a cure for an incurable problem that saves millions from amputation and death, I think that would be great. How many people give money to a charity where they get nothing in return except another letter asking for more donations? If you invest in a Medical Research Study to treat chronic wounds, heart disease, diabetes, dementia, cancer, and autism, you may profit if it succeeds. That is what free enterprise is all about: success equals rewards, and failure means try again. The management of the Michael J. Fox Foundation has earned millions in salaries and perks, yet has not advanced any real results for Parkinson's disease. Look at your dollar and ask yourself: do you want to bet on someone who has failed after 20 years, spending \$3 billion, or on that Zhittya junkyard dog that gets it done?

Background and Type 2 Diabetes Medical Research 1st Glance Report by Vika & Sergiy Montano

We are thrilled to share the latest developments from our groundbreaking Type 2 Diabetes Research Study, which officially kicked off in Las Vegas, Nevada, on September 22, 2025. We began dosing our first cadre of five patients as part of a larger planned study involving 100 participants. This initial phase has been designed to ensure a smooth rollout, and we're already seeing promising signs that underscore the potential of our innovative approach using FGF-1 to address what we and other researchers believe is the root cause of type 2 diabetes: the decline of the glucose-sensing neurons in the brain, which leads to high levels of glucose, causing insulin resistance.

To minimize any technical hurdles during this early stage, we selected five initial patients from the Las Vegas area. This localized focus enabled our team to provide hands-on support, rapid troubleshooting, and a controlled environment in which we could refine our protocols before expanding further. At the heart of our monitoring strategy are some of the most advanced continuous glucose monitors (CGMs) available on the market today. These state-of-the-art devices enable us to remotely access real-time glucose measurements, providing continuous visibility into each patient's readings. Data is collected every ~10-15 minutes and securely stored in our custom-built database, a cutting-edge system tailored specifically for this study that aligns with the highest standards for clinical research.

Our team has been operating in an all-hands-on-deck mode to ensure seamless data integration and collection. While both Sergiy and I would like to believe we can do everything ourselves, we knew we would need help. Before starting our study, we reached out to our long-term partners at the University of Nevada, Reno, and the Nevada Center for Applied Research (NCAR), who connected us with some of Nevada's upcoming professionals. As a result, we have brought on two outstanding experts in their fields.

One of these leaders is our newly hired Clinical Trial Manager, Jacqueline Arevalo. She has expertise in FDA-regulated clinical trials involving human subjects and hands-on laboratory experience. Moreover, she has been personally touched by type 2 diabetes and has an incredible knowledge of diabetes management. She's been working tirelessly alongside our patients, nurses, and staff to coordinate everything from device installations to data collection, ensuring every aspect runs smoothly.

Complementing her on the technical front is Owen Boxx, our technology specialist, who has extensive experience in database management and was the primary developer behind a biometric control device. Owen has been pivotal in securing and processing our live data feeds. The software we've deployed is incredibly advanced, integrating multiple platforms into a unified database and server architecture that enables real-time analysis and robust security. Owen puts the tech in biotech!

Finally, the nurses and doctors at our partnering clinic in Las Vegas have been great resources for blood draws for biomarker analysis, glucose level assessments, and the installation of new CGM devices.

Results and Hurdles

Now, roughly three weeks post-initial dosing, the early results are highly encouraging and point to the transformative potential of FGF-1 therapy. All five patients entered the study as confirmed type 2 diabetics, many with longstanding challenges in managing their condition. We're monitoring a range of metrics, including blood glucose trends, medication adjustments, and overall metabolic stability, and the data so far suggest meaningful improvements across the board.

One case involves a patient who has **successfully discontinued his diabetes medication entirely** while maintaining blood glucose levels firmly within the target range (70 mg/dL–180 mg/dL). This outcome unfolded remarkably quickly. Initially, this patient continued his standard medication regimen alongside our

FGF-1 treatment. Within 10 days, the patient's glucose levels dipped into potentially unhealthy lows. This was a clear sign that the therapy was already exerting a powerful normalizing effect. Upon our doctor's recommendation to cease the medication, his levels stabilized at normal, healthy values and have not exceeded the target range since. This rapid response not only highlights the efficacy of FGF-1 but also underscores the importance of personalized monitoring in our protocol. Below is a copy of our remote-access portal. First, you will see the patient's previous medication dropping his levels into unhealthy lows, and after that, you will see this patient's blood glucose levels normalize without any medication:


THU Oct 9



Glucose mg/dL

Max

Min



SAT Oct 11



Glucose mg/dL

Max

Min



Another patient has achieved a significant milestone by reducing her medication dosage by half while consistently staying within the target blood glucose range. This adjustment reflects a steady improvement in their metabolic control. Again, you will see her medication forcing her blood-glucose levels to drop into unhealthy lows, a sign for her to reduce her medication, and her continued normalized blood-glucose level:


TUE Sep 30



Glucose mg/dL

Max

Min




FRI Oct 10




Glucose mg/dL

Max

Min



In a third case, we observed a notable downward decrease in blood glucose for a patient who had historically struggled with glucose management. While not yet fully stabilized, these trends are promising, and our team is optimistic that they'll reach and sustain the target range in the coming days or weeks as the therapy continues to take effect. Please note that any number highlighted in orange is considered an unhealthily high level; in these patients, we aim to see reductions in those numbers. Below you will see a comparison of Saturday, October 4, 2025, and Saturday, October 11, 2025:



While not yet perfect, we believe that this patient is trending towards improvement and has not adjusted his medication.

We did encounter a hurdle with one patient. It's worth noting that not all our participants entered the study with established habits for glucose management. This **one patient had never actively managed her blood glucose before enrolling**, a common challenge in real-world diabetes care that we had not seen before. For her, the study introduced not just our FGF-1 treatment but also constant access to real-time blood-glucose data, which proved eye-opening. **Prior to dosing, her levels were consistently at unhealthy highs.** After seeing her incredibly high readings and worrying about her health, she self-administered an emergency dose of GLP-1 medication (a short-acting intervention with an effective half-life of about seven days). We're now closely monitoring her progress to determine whether her glucose levels rebound to abnormal highs once the GLP-1 wears off or if the sustained effects of FGF-1 maintain them within the target range.

Finally, we have a patient whose daily average blood glucose has shown a consistent downward trend for the last 7 days. This positive trajectory has our team hopeful that she'll soon be able to further reduce or potentially eliminate her medication needs, building on what we've seen in the group overall.

In general trends, when reviewing the hourly glucose readings, a decline was observed in participants' glucose levels within 4 hours of dosing.

This early data from our Las Vegas cadres is just the beginning, but they paint a vivid picture of the fantastic work happening at Zhittya Genesis Medicine. By combining cutting-edge biotechnology with advanced digital tools and a world-class team, we're advancing the science of diabetes treatment and improving lives in tangible ways. As we continue to dose additional patients and gather more data, we'll keep you updated on our progress. Stay tuned for more exciting developments in the months ahead!

Type 2 Diabetes Patient Comment:

To: vika@zhittyamedicine.com

Subject: Type 2 Diabetes Study Statement

Good day to each of you!

I want to thank Zhittya for the opportunity to participate in this important study which could mean so much to so many.

My experience with the team has developed into friendships which will last beyond the study because of the qualities of each individual.

I want to give you an overview of my experience specific to the treatments. When I started the protocols my main concern was my type 2 diabetes which was causing bleeding in my eyes as a result of Proliferative Diabetic Retinopathy at the same time I was experiencing debilitating headaches emanating from the right side of my head which would travel to the front and across my forehead and eyes (documents and scan results provided).

With each of the treatment sessions I noticed my insulin needs stabilizing and the dosage required being reduced by as much as 50%, from 40 units per day to 20 units per day.

Equally as remarkable as the decrease in insulin requirements is the fact during the treatment sessions the bleeding in my eyes seemed to be reduced to the point I can no longer say I am experiencing ongoing symptoms as well as my headaches did return during the rest/off treatment period but at less than 50% of the intensity.

Throughout the study at this point I have realized the importance physical activity and its affect on the effectiveness of the treatment. I noticed a difference during a period of high to moderate activity to a recent weekend when I was bound

watching everyone's pets. These pets are much too large for me to take on walks.

To summarize, my insulin requirements have been reduced by 50% and at this point in the study I feel I have been given a new outlook on life with effect to the treatments have had on my headaches. I am excited to experience the long term effects of the study and pray for everyone's success.

Maria XXXXXXX

Vika Parkinson's Patients emails

Dear Vika,

I am happy to report to you that I have been able to stop using carbodopa/levadopa. I have gone unmedicated for 6 days.

During this process, I realized it was the side effects of the medication that was "keeping me sick." My nocturnal kicking and foot cramps have stopped, my constipation is noticeably improved, I am sleeping better and my tremor is almost absent. I have increased energy and my bouts of fatigue are fewer.

I have been extremely stiff in my hips when I get up in the morning, but it resolves as I move and remain active throughout the day. I continue to struggle with scoliosis and significant posture changes. This may be unrelated to Parkinson's.

I am going to reach out to Monique and schedule my July Video Evaluation.

I am excited and encouraged by my progress. Vika, thank you for giving me hope and renewing my excitement about the future!

Judy XXXXXXX, Cohort 32

Vika

Greetings to you!

I have been overall doing well.

My cataract surgery in both my eyes this summer was successful.

I continue to stay busy with my responsibilities. I am in the process of having a swimming pool completed at my farm to be able to do more exercise to strengthen my muscles especially my right leg.

I have been taking the following regimen of medication:

Sinemet 25- 100 mg MG 2 tabs every am;

Rasagiline 1 MG one tab every am; and

Lisinopril 10 MG one tab every morning.

Since I began as a research participant for fgf-1, I have been able to stop taking Amantadine and Mirapex. With the present dosing of meds, I am "Cinderella-free" of bothersome symptoms for about 6 hrs, but after that 6 hr period, my bothersome symptoms return as in the story of Cinderella her carriage at midnight turns back into a pumpkin and her carriage horsemen return to her pet animals and her beautiful gown turns into rags.

I believe that I am making some progress. My neurologist visit this past summer went well. My neurologist is pleased to see how I am doing on reduced meds.

I am also enjoying the return of my handwriting. It seems to be back to normal 24 hrs day and returned to normal this summer and continues to be normal.

I send this note to communicate my continued progress, slow but real.

I continue to remain focused on reducing my sinemet as I work to resolve the abnormalities of dragging my right foot when I walk and the weakness in my right leg and foot.

Thank you so much. I believe that fgf-1 is helping me. I work towards getting better with the help of God and with the continued efforts your company is doing to help me.

With much appreciation,
R. Christine XXXXXX

Zhittya's Medical Research Studies Funding

Funding for the Medical Research Study to "Reverse Type 2 Diabetes" continues. We have about 70% committed of the \$5 million we wish to raise to fund the first 100-person study in Las Vegas. I believe we will be able to finish the funding for the Type 2 diabetes study within 60 days. As we develop more data, Zhittya may succeed in reversing type 2 diabetes. Investors like the 10 times return on their money more; as the early results show, it is working. I hope to have the results of this study in the 2nd quarter of 2026; it would make for a great press announcement: We reversed type 2 diabetes!

With the warm reception we have had from investors about the type 2 diabetes medical research funding, I have decided to start the Medical Research Study for "Healing Chronic Wounds." We are offering the same ten times upside as a royalty of the cash Zhittya earns from the sale of the FGF-1 medicine to heal chronic wounds. The difference is that we will pay a royalty of 50% of the cash

receipts to the investors until they max out at 10 times their investment. We are doing this since I believe: (1) we have 40 years of data, which shows me a 99.9% likelihood of success; (2) nonhealing wounds are a major unmet medical need (estimated 6.5 million in the USA every year alone); and (3) the drug is delivered topically, which should allow it to move more quickly to approval. I believe if we start dosing in December 2025 and dose the 100th patient in March 2026 (with an estimated 4 to 5 months to heal the worst of the worst wounds), that should give us results by August of 2026. Zhittya should have a wonderful announcement for the millions of people being harmed by a lack of treatment for their non-healing chronic wounds.

Future Medical Research Studies

At the NIBA meeting, a man came to me and asked me about autism. I told him we had dosed two patients in their 20s, and the results have shown modest improvements; however, we believe that enhancing the development of more blood vessels in their brains and the formation of new neurons will take more time. However, we do not know. We believe underdeveloped vascularization is the fundamental cause, so in theory it could work, but it could take a long time, several years perhaps. He told me when we were ready, he would invest **big time in autism**. Zhittya will take our molecule, and we will try many medical applications for diseases. Look at our past Updates, our brochures. Nine months ago, we never mentioned type 2 diabetes, because we had no idea FGF-1 could do what we are doing. Today, I believe FGF-1 can do in humans what it did in rodents: REVERSE TYPE 2 DIABETES. In this type 2 diabetes study, we are testing whether FGF-1 can enhance pancreatic and liver function, as reported by medical scientists in Asia. New things are coming fast as we learn what FGF-1 can do.

Medical Research Studies Funding Investment Opportunity.

If you have an interest in learning about the Medical Research Study Funding investment opportunity (minimum investment \$25,000), please email me at: Dan333@aol.com or call me at 702-802-8373.

Cross Border Medical Tourism

Cross Border Medical Tourism services are for those people who want to be considered for Zhittya's future clinical trials or its current Medical Research Studies. Cross Border's focus is to fill all available slots for Medical Research Studies in the British Virgin Islands and The Bahamas while we wait for other

clinics to come online.

Cross Border is working on filling the available slots for the next BVI Medical Research Studies (intranasal FGF-1 for Parkinson's disease) on the following dates:

Cohort #41: October 24 – 29, 2025

Cohort #42: December 3 – 8, 2025

Please get in touch with Sam Cross at Cross Border Medical if you wish to be considered for the BVI cohorts. Sam's email address is:

sam.crossbordermedical@gmail.com.

In addition, if you are interested in participating in a functional MRI brain scan study, which will take place at Washington University in St. Louis, please let Sam know. There is a finite number of slots for the imaging studies. These studies will look at brain blood flow before and after treatment with FGF-1.

Events:

Saturday, October 18: Aging Wellness Expo, sponsored by the Las Vegas Review-Journal at the Rio Convention Center in Las Vegas, Nevada.

Open from 9:00 AM to 2:00 PM

Dan Montano and John Laub will speak at 10:30 AM on Parkinson's disease and Strokes.

Vika Montano and Sergiy Montano will be speaking at 12:30 PM on type 2 diabetes.

Thursday, October 23: Southern California Investment Forum, sponsored by the Global Capital Network in Carlsbad, California

Dan Montano will be speaking on: **Breakthrough Biotech Medicine: Treating the Cause of Death of 65% of All Adults.**

If you are in northern San Diego County or southern Orange County, consider coming. If you have diabetes, you may want to come to learn if you have something to lose-diabetes.

Friday, October 24: Regenerative Medicine Conference in at the J.W. Marriott Hotel in Dubai

Speaker: Dr. Omar Hallak, Chief Cardiovascular Doctor at King's College Hospital, Dubai

Topic: FGF-1 Reversing Parkinson's Disease in Medical Research Studies

December 9–11: Home Offices Investors Annual Summit at the Westin Ft. Lauderdale Beach Resort

Tuesday, December 9, at 3:30 PM: Dan Montano on: **Breakthrough Biotech Medicine: Treating the Cause of Death of 65% of all Adults**

Conclusion by Dan Montano

Today, Friday, October 17, Zhittya's Monthly Update has a lot of data. I look in front of us for the next 9 months, and I see clear sailing in front of us now. We have survived the violent business storms of the Great Financial Crisis and COVID-19 and countless minor storms. We have accomplished what no other pharmaceutical company in the world has done: (1) grown fresh blood vessels in the heart to treat the #1 cause of death in the world, (2) enhanced Parkinson's disease patients' lives, and (3) reversed type 2 diabetes in 25 people, and I could name many more breakthroughs than that. Now I feel the wind on our backs and clear skies ahead of us. We are dosing Parkinson's disease and type 2 diabetes patients and learning how to do better. So, much of what we have worked for 27 years is coming together now. I am 100% committed to treating no-option heart patients in 2026. Millions of people should not have to die because the FDA is a bureaucracy that does not care about the real medical needs of humans.

Vika is managing the type 2 diabetes study. She has been getting up at 5:00 AM and working until midnight every day for three weeks. She and Sergiy have been with our test subjects at every dosing. They read the glucose readouts, studying each patient's change. For those of you who know me, I have always said, "I am not smart, I am not lucky, but no one outworks me!" Today, I stand corrected. Vika and Sergiy have outworked everyone to advance this treatment for diabetes. Our people in Reno, making the FGF-1 in our lab, are an amazing team, doing the impossible with 1% of the tools of Big Pharma and still outproducing them with better results. I am proud of the Band of Brothers who have come together to accomplish what everyone said was impossible. **To our investors, thank you; your rewards are coming soon. To our patients: Thank you; your faith in us has been our secret sauce to success.** For those of you who have doubted us: I am sorry we are going to break your hearts with our success. I can smell it, the sweet smell of success. Zhittya is turning home after this long voyage into the harsh unknown. When I see my partners, investors, and patients doing the work to save lives and lessen pain and suffering in the future, I am proud; **we are good people!**

Thank you all for standing beside us in this long and harsh voyage. I can finally see our home port; **we have made it!**

I pray we all succeed! Bless you all!

Dan Montano, CEO
Zhittya Genesis Medicine
8683 W. Sahara Ave., Suite 280
Las Vegas, NV 89117
USA

zgm.care